A Web-Based Cognitive Bias Modification Intervention (Re-train Your Brain) for Emerging Adults With Co-occurring Social Anxiety and Hazardous Alcohol Use: Protocol for a Multiarm Randomized Controlled Pilot Trial.

alcohol anxiety approach bias cognitive bias modification emerging adults interpretation bias

Journal

JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504

Informations de publication

Date de publication:
07 Jul 2021
Historique:
received: 10 03 2021
accepted: 26 05 2021
revised: 26 05 2021
entrez: 13 7 2021
pubmed: 14 7 2021
medline: 14 7 2021
Statut: epublish

Résumé

Alcohol use and anxiety disorders commonly co-occur, resulting in a more severe clinical presentation and poorer response to treatment. Research has shown that approach bias modification (ApBM) and interpretation bias modification (IBM) cognitive retraining interventions can be efficacious adjunctive treatments that improve outcomes for alcohol use and social anxiety, respectively. However, the acceptability, feasibility, and clinical utility of combining ApBM and IBM programs to optimize treatments among comorbid samples are unknown. It is also unclear whether integrating ApBM and IBM within each training session or alternating them between each session is more acceptable and efficacious. This paper describes the protocol for a randomized controlled pilot trial investigating the feasibility, acceptability, and preliminary efficacy of the Re-train Your Brain intervention-an adjunct web-based ApBM+IBM program-among a clinical sample of emerging adults with hazardous alcohol use and social anxiety. The study involves a three-arm randomized controlled pilot trial in which treatment-seeking emerging adults (18-30 years) with co-occurring hazardous alcohol use and social anxiety will be individually randomized to receive the Re-train Your Brain integrated program, delivered with 10 biweekly sessions focusing on both social anxiety and alcohol each week, plus treatment as usual (TAU; ie, the model of care provided in accordance with standard practice at their service; n=30); the Re-train Your Brain alternating program, delivered with 10 biweekly sessions focusing on social anxiety one week and alcohol the next week, plus TAU (n=30); or TAU only (n=30). Primary outcomes include feasibility (uptake, follow-up rates, treatment adherence, attrition, and adverse events) and acceptability (system usability, client satisfaction, user experience, and training format preference). Secondary efficacy outcomes include changes in alcohol approach and interpretation biases, social anxiety, and alcohol use (eg, drinks per day, binge drinking, drinking motives, severity of dependence, and cravings). The primary end point will be posttreatment (6 weeks postbaseline), with a secondary end point at 3 months postbaseline. Descriptive statistics will be conducted for primary outcomes, whereas intention-to-treat, multilevel mixed effects analysis for repeated measures will be performed for secondary outcomes. This study is funded from 2019 to 2023 by Australian Rotary Health. Recruitment is expected to be completed by mid-2022 to late 2022, with follow-ups completed by early 2023. This study will be the first to evaluate whether an ApBM+IBM program is acceptable to treatment-seeking, emerging adults and whether it can be feasibly delivered via the web, in settings where it will ultimately be used (eg, at home). The findings will broaden our understanding of the types of programs that emerging adults will engage with and whether the program may be an efficacious treatment option for this comorbidity. Australian New Zealand Clinical Trials Registry ACTRN12620001273976; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364131. PRR1-10.2196/28667.

Sections du résumé

BACKGROUND BACKGROUND
Alcohol use and anxiety disorders commonly co-occur, resulting in a more severe clinical presentation and poorer response to treatment. Research has shown that approach bias modification (ApBM) and interpretation bias modification (IBM) cognitive retraining interventions can be efficacious adjunctive treatments that improve outcomes for alcohol use and social anxiety, respectively. However, the acceptability, feasibility, and clinical utility of combining ApBM and IBM programs to optimize treatments among comorbid samples are unknown. It is also unclear whether integrating ApBM and IBM within each training session or alternating them between each session is more acceptable and efficacious.
OBJECTIVE OBJECTIVE
This paper describes the protocol for a randomized controlled pilot trial investigating the feasibility, acceptability, and preliminary efficacy of the Re-train Your Brain intervention-an adjunct web-based ApBM+IBM program-among a clinical sample of emerging adults with hazardous alcohol use and social anxiety.
METHODS METHODS
The study involves a three-arm randomized controlled pilot trial in which treatment-seeking emerging adults (18-30 years) with co-occurring hazardous alcohol use and social anxiety will be individually randomized to receive the Re-train Your Brain integrated program, delivered with 10 biweekly sessions focusing on both social anxiety and alcohol each week, plus treatment as usual (TAU; ie, the model of care provided in accordance with standard practice at their service; n=30); the Re-train Your Brain alternating program, delivered with 10 biweekly sessions focusing on social anxiety one week and alcohol the next week, plus TAU (n=30); or TAU only (n=30). Primary outcomes include feasibility (uptake, follow-up rates, treatment adherence, attrition, and adverse events) and acceptability (system usability, client satisfaction, user experience, and training format preference). Secondary efficacy outcomes include changes in alcohol approach and interpretation biases, social anxiety, and alcohol use (eg, drinks per day, binge drinking, drinking motives, severity of dependence, and cravings). The primary end point will be posttreatment (6 weeks postbaseline), with a secondary end point at 3 months postbaseline. Descriptive statistics will be conducted for primary outcomes, whereas intention-to-treat, multilevel mixed effects analysis for repeated measures will be performed for secondary outcomes.
RESULTS RESULTS
This study is funded from 2019 to 2023 by Australian Rotary Health. Recruitment is expected to be completed by mid-2022 to late 2022, with follow-ups completed by early 2023.
CONCLUSIONS CONCLUSIONS
This study will be the first to evaluate whether an ApBM+IBM program is acceptable to treatment-seeking, emerging adults and whether it can be feasibly delivered via the web, in settings where it will ultimately be used (eg, at home). The findings will broaden our understanding of the types of programs that emerging adults will engage with and whether the program may be an efficacious treatment option for this comorbidity.
TRIAL REGISTRATION BACKGROUND
Australian New Zealand Clinical Trials Registry ACTRN12620001273976; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=364131.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) UNASSIGNED
PRR1-10.2196/28667.

Identifiants

pubmed: 34255726
pii: v10i7e28667
doi: 10.2196/28667
pmc: PMC8295835
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e28667

Informations de copyright

©Katrina Prior, Elske Salemink, Reinout W Wiers, Bethany A Teachman, Monique Piggott, Nicola C Newton, Maree Teesson, Andrew J Baillie, Victoria Manning, Lauren F McLellan, Alison Mahoney, Lexine A Stapinski. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 07.07.2021.

Références

Lancet Psychiatry. 2020 Jun;7(6):465-467
pubmed: 32445673
Addict Behav. 2007 Nov;32(11):2611-32
pubmed: 17716823
JMIR Ment Health. 2019 Oct 24;6(10):e11841
pubmed: 31651410
J Consult Clin Psychol. 2003 Dec;71(6):1058-67
pubmed: 14622081
Trials. 2014 Jul 03;15:264
pubmed: 24993581
Alcohol Res. 2012;34(4):414-31
pubmed: 23584108
Arch Gen Psychiatry. 2004 Mar;61(3):310-7
pubmed: 14993119
Alcohol Clin Exp Res. 2014 Feb;38(2):587-94
pubmed: 24164417
Annu Rev Clin Psychol. 2016;12:281-305
pubmed: 27019398
Alcohol Clin Exp Res. 2020 Nov;44(11):2283-2297
pubmed: 33146919
Alcohol Alcohol. 2012 Mar-Apr;47(2):143-8
pubmed: 22215000
Behav Res Ther. 2007 Jul;45(7):1517-29
pubmed: 17349970
J Behav Ther Exp Psychiatry. 2015 Dec;49(Pt A):21-9
pubmed: 26005201
Cogn Emot. 2018 Nov;32(7):1478-1486
pubmed: 28366048
J Stud Alcohol Drugs. 2018 May;79(3):333-343
pubmed: 29885138
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
J Consult Clin Psychol. 1991 Feb;59(1):12-9
pubmed: 2002127
Addict Behav. 2015 Jan;40:21-6
pubmed: 25218067
Arch Gen Psychiatry. 2004 Aug;61(8):807-16
pubmed: 15289279
Psychol Assess. 2012 Mar;24(1):66-76
pubmed: 21744971
Lancet Psychiatry. 2020 Jun;7(6):506-514
pubmed: 32445689
BMC Psychiatry. 2019 Jul 23;19(1):225
pubmed: 31337373
Alcohol Clin Exp Res. 2016 Sep;40(9):1945-52
pubmed: 27421061
Genes Brain Behav. 2009 Feb;8(1):101-6
pubmed: 19016889
BMC Med Res Methodol. 2010 Jan 06;10:1
pubmed: 20053272
Psychosomatics. 2009 Nov-Dec;50(6):613-21
pubmed: 19996233
J Abnorm Psychol. 2000 Nov;109(4):602-15
pubmed: 11195984
Br J Psychiatry. 2017 Nov;211(5):266-271
pubmed: 29092835
Aust N Z J Psychiatry. 2015 Mar;49(3):227-35
pubmed: 25122449
BMC Med Res Methodol. 2010 Jul 16;10:67
pubmed: 20637084
Front Psychiatry. 2020 Jan 09;10:871
pubmed: 31998146
J Child Psychol Psychiatry. 2018 Nov;59(11):1127-1142
pubmed: 29052865
Am J Psychiatry. 2017 Aug 1;174(8):775-784
pubmed: 28407726
Behav Res Ther. 2016 Dec;87:58-69
pubmed: 27591918
Alcohol Clin Exp Res. 2005 Aug;29(8):1432-43
pubmed: 16131851
Addict Behav. 2017 Jan;64:21-28
pubmed: 27538198
Psychol Sci. 2011 Apr;22(4):490-7
pubmed: 21389338
Eur Psychiatry. 2015 Jan;30(1):128-36
pubmed: 24630346
Psychol Addict Behav. 2017 Mar;31(2):171-179
pubmed: 27935726
Arch Gen Psychiatry. 2005 Jun;62(6):593-602
pubmed: 15939837
J Med Internet Res. 2016 Mar 23;18(3):e71
pubmed: 27009465
Depress Anxiety. 2011 Nov;28(11):981-8
pubmed: 21898705
Br J Psychiatry. 2015 Jan;206(1):7-16
pubmed: 25561486
Behav Ther. 2019 May;50(3):515-530
pubmed: 31030870
Addict Behav. 2012 Jul;37(7):824-30
pubmed: 22459327
J Affect Disord. 2017 Dec 1;223:175-183
pubmed: 28759865
J Fam Pract. 2014 Sep;63(9):524-30
pubmed: 25353031
Anxiety Stress Coping. 2018 Nov;31(6):669-685
pubmed: 30235946
Behav Res Ther. 2013 Jul;51(7):344-51
pubmed: 23639300
Addict Behav. 2010 Jan;35(1):42-5
pubmed: 19733441
Br J Addict. 1983 Jun;78(2):145-55
pubmed: 6135435
Can J Psychiatry. 2017 Apr;62(4):237-246
pubmed: 27310233
Neuropsychol Rev. 2019 Mar;29(1):52-78
pubmed: 30644025
J Consult Clin Psychol. 2012 Dec;80(6):1021-33
pubmed: 22963595
J Behav Ther Exp Psychiatry. 2011 Sep;42(3):258-64
pubmed: 21349242
Psychol Addict Behav. 2012 Sep;26(3):672-7
pubmed: 22486334
J Behav Ther Exp Psychiatry. 2014 Mar;45(1):186-95
pubmed: 24177146
JMIR Res Protoc. 2019 Apr 12;8(4):e12370
pubmed: 30977742
Dev Cogn Neurosci. 2013 Apr;4:38-51
pubmed: 23218805
JAMA Psychiatry. 2021 Feb 1;78(2):133-140
pubmed: 33146693
J Consult Clin Psychol. 2012 Jun;80(3):497-511
pubmed: 22250851
Nervenarzt. 2016 Jan;87(1):13-25
pubmed: 26670021
J Affect Disord. 2015 Jun 1;178:121-30
pubmed: 25805404
Cochrane Database Syst Rev. 2009 Jul 08;(3):MR000008
pubmed: 19588449
J Consult Clin Psychol. 2015 Dec;83(6):1108-22
pubmed: 26302248
Eval Program Plann. 1979;2(3):197-207
pubmed: 10245370
Addiction. 2010 Dec;105(12):2085-94
pubmed: 20707771
PLoS One. 2016 Sep 09;11(9):e0162226
pubmed: 27611692
Stat Methods Med Res. 2016 Jun;25(3):1057-73
pubmed: 26092476
J Anxiety Disord. 2009 Jun;23(5):676-83
pubmed: 19272750
J Behav Ther Exp Psychiatry. 2010 Jun;41(2):140-4
pubmed: 19962127
Alcohol Clin Exp Res. 2016 Sep;40(9):2011-9
pubmed: 27488392
J Consult Clin Psychol. 2018 Dec;86(12):1005-1016
pubmed: 30507226
J Stud Alcohol Drugs. 2012 Sep;73(5):829-33
pubmed: 22846247
Psychol Med. 2010 Jun;40(6):977-88
pubmed: 20441690
BMJ Open. 2014 Feb 04;4(2):e003821
pubmed: 24496696

Auteurs

Katrina Prior (K)

The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, Australia.

Elske Salemink (E)

Experimental Psychopathology Lab, Department of Clinical Psychology, Utrecht University, Utrecht, Netherlands.

Reinout W Wiers (RW)

Addiction Development and Psychopathology (ADAPT) Lab, Department of Psychology, University of Amsterdam, Amsterdam, Netherlands.
Center for Urban Mental Health, University of Amsterdam, Amsterdam, Netherlands.

Bethany A Teachman (BA)

Department of Psychology, School of Arts and Sciences, University of Virginia, Virginia, VA, United States.

Monique Piggott (M)

The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, Australia.

Nicola C Newton (NC)

The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, Australia.

Maree Teesson (M)

The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, Australia.

Andrew J Baillie (AJ)

Sydney School of Health Sciences, The University of Sydney, Sydney, Australia.

Victoria Manning (V)

Eastern Health Clinical School, Faculty of Medicine, Nursing & Health Sciences, Monash University, Melbourne, Australia.

Lauren F McLellan (LF)

Centre for Emotional Health, Department of Psychology, Macquarie University, Sydney, Australia.

Alison Mahoney (A)

Clinical Research Unit for Anxiety and Depression, St Vincent's Public Hospital, Sydney, Australia.

Lexine A Stapinski (LA)

The Matilda Centre for Research in Mental Health and Substance Use, The University of Sydney, Sydney, Australia.

Classifications MeSH